Vitamin E metabolic effects and genetic variants: A challenge for precision nutrition in obesity and associated disturbances

Nutrients

Volumn 10, Issue 12, 2018, Pages

  Galmés, Sebastià ^a,b,c   Serra, Francisca ^a,b,c   Palou, Andreu ^a,b,c  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c HEALTH RESEARCH INSTITUTE OF THE BALEARIC ISLANDS IDISBA   (Spain)

Author keywords

Genetic variant; Metabolic syndrome; Nutrigenetics; Obesity; Tocopherol; Vitamin E

Indexed keywords

ABC TRANSPORTER A1; ALPHA TOCOPHEROL; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CD36 ANTIGEN; CHOLESTEROL; CYTOCHROME P450; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; LIPOPOLYSACCHARIDE; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SCAVENGER RECEPTOR BI; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ALLELE; ANTIOXIDANT ACTIVITY; BILE SECRETION; BIOAVAILABILITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DNA POLYMORPHISM; DYSLIPIDEMIA; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LIPID METABOLISM; LIVER METABOLISM; NIEMANN PICK DISEASE; NUTRITION; OBESITY; OXIDATIVE STRESS; PROTEIN TRANSPORT; REVIEW; RISK FACTOR; VITAMIN BLOOD LEVEL; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION; GENETICS; METABOLIC SYNDROME X; METABOLISM; NUTRIGENOMICS; NUTRITIONAL STATUS; PHYSIOLOGY;

HUMANS; METABOLIC SYNDROME; NUTRIGENOMICS; NUTRITIONAL STATUS; OBESITY; VITAMIN E;

EID: 85057971939     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu10121919     Document Type: Review

References (162)

1. Jiang, Q.; Christen, S.; Shigenaga, M.K.; Ames, B.N. gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. Am. J. Clin. Nutr. 2001, 74, 714–722. [CrossRef] [PubMed]
2. Polito, A.; Intorre, F.; Andriollo-Sanchez, M.; Azzini, E.; Raguzzini, A.; Meunier, N.; Ducros, V.; O’Connor, J.M.; Coudray, C.; Roussel, A.M.; et al. Estimation of intake and status of vitamin A, vitamin E and folate in older European adults: The ZENITH. Eur. J. Clin. Nutr. 2005, 59, 42. [CrossRef] [PubMed]
3. Krumova, K.; Friedland, S.; Cosa, G. How lipid unsaturation, peroxyl radical partitioning, and chromanol lipophilic tail affect the antioxidant activity of α-tocopherol: Direct visualization via high-throughput fluorescence studies conducted with fluorogenic α-tocopherol analogues. J. Am. Chem. Soc. 2012. [CrossRef] [PubMed]
4. EFSA. Scientific Opinion on the substantiation of health claims related to vitamin E and protection of DNA, proteins and lipids from oxidative damage, maintenance of the normal function of the immune system. EFSA J. 2010, 8, 1816. [CrossRef]
5. Galli, F.; Azzi, A.; Birringer, M.; Cook-Mills, J.M.; Eggersdorfer, M.; Frank, J.; Cruciani, G.; Lorkowski, S.; Özer, N.K. Vitamin E: Emerging aspects and new directions. Free Radic. Biol. Med. 2017, 102, 16–36. [CrossRef]
6. Cervantes, B.; Ulatowski, L.M. Vitamin E and Alzheimer’s Disease—Is It Time for Personalized Medicine? Antioxidants 2017, 6, 45. [CrossRef]
7. Azzi, A. Many tocopherols, one vitamin E. Mol. Aspects Med. 2018, 61, 92–103. [CrossRef]
8. Zingg, J.-M. Vitamin E: A Role in Signal Transduction. Annu. Rev. Nutr. 2015, 35, 135–173. [CrossRef]
9. Mocchegiani, E.; Costarelli, L.; Giacconi, R.; Malavolta, M.; Basso, A.; Piacenza, F.; Ostan, R.; Cevenini, E.; Gonos, E.S.; Franceschi, C.; et al. Vitamin E–gene interactions in aging and inflammatory age-related diseases: Implications for treatment. A systematic review. Ageing Res. Rev. 2014, 14, 81–101. [CrossRef]
10. Ulatowski, L.; Manor, D. Vitamin E trafficking in neurologic health and disease. Annu. Rev. Nutr. 2013, 33, 87–103. [CrossRef]
11. Schmölz, L. Complexity of vitamin E metabolism. World J. Biol. Chem. 2016, 7, 14. [CrossRef] [PubMed]
12. Zhao, L.; Fang, X.; Marshall, M.; Chung, S. Regulation of Obesity and Metabolic Complications by Gamma and Delta Tocotrienols. Molecules 2016, 21, 344. [CrossRef]
13. Wong, S.K.; Chin, K.-Y.; Suhaimi, F.H.; Ahmad, F.; Ima-Nirwana, S. Vitamin E As a Potential Interventional Treatment for Metabolic Syndrome: Evidence from Animal and Human Studies. Front. Pharmacol. 2017, 8, 444. [CrossRef] [PubMed]
14. European Food Safety Authority (EFSA). Scientific Opinion on Dietary Reference Values for vitamin E as α-tocopherol. EFSA J. 2015, 13, 4149. [CrossRef]
15. Péter, S.; Friedel, A.; Roos, F.F.; Wyss, A.; Eggersdorfer, M.; Hoffmann, K.; Weber, P. A systematic review of global alpha-tocopherol status as assessed by nutritional intake levels and blood serum concentrations. Int. J. Vitam. Nutr. Res. 2015, 85, 261–281. [CrossRef] [PubMed]
16. Pereira-Santos, M.; Costa, P.R.F.; Assis, A.M.O.; Santos, C.A.S.T.; Santos, D.B. Obesity and vitamin D deficiency: A systematic review and meta-analysis. Obes. Rev. 2015, 16, 341–349. [CrossRef] [PubMed]
17. Godala, M.M.; Materek-Kuśmierkiewicz, I.; Moczulski, D.; Rutkowski, M.; Szatko, F.; Gaszyńska, E.; Tokarski, S.; Kowalski, J. Lower Plasma Levels of Antioxidant Vitamins in Patients with Metabolic Syndrome: A Case Control Study. Adv. Clin. Exp. Med. 2016, 25, 689–700. [CrossRef]
18. Waniek, S.; di Giuseppe, R.; Plachta-Danielzik, S.; Ratjen, I.; Jacobs, G.; Koch, M.; Borggrefe, J.; Both, M.; Müller, H.-P.; Kassubek, J.; et al. Association of Vitamin E Levels with Metabolic Syndrome, and MRI-Derived Body Fat Volumes and Liver Fat Content. Nutrients 2017, 9, 1143. [CrossRef]
19. Lee, I.-M.; Cook, N.R.; Gaziano, J.M.; Gordon, D.; Ridker, P.M.; Manson, J.E.; Hennekens, C.H.; Buring, J.E. Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer. JAMA 2005, 294, 56. [CrossRef]
20. Loffredo, L.; Perri, L.; Di Castelnuovo, A.; Iacoviello, L.; De Gaetano, G.; Violi, F. Supplementation with vitamin E alone is associated with reduced myocardial infarction: A meta-analysis. Nutr. Metab. Cardiovasc. Dis. 2015, 25, 354–363. [CrossRef]
21. Schürks, M.; Glynn, R.J.; Rist, P.M.; Tzourio, C.; Kurth, T. Effects of vitamin E on stroke subtypes: Meta-analysis of randomised controlled trials. BMJ 2010, 341, c5702. [CrossRef] [PubMed]
22. Kelly, F.J.; Lee, R.; Mudway, I.S. Inter-and Intra-Individual Vitamin E Uptake in Healthy Subjects Is Highly Repeatable across a Wide Supplementation Dose Range. Ann. N. Y. Acad. Sci. 2004, 1031, 22–39. [CrossRef] [PubMed]
23. Major, J.M.; Yu, K.; Wheeler, W.; Zhang, H.; Cornelis, M.C.; Wright, M.E.; Yeager, M.; Snyder, K.; Weinstein, S.J.; Mondul, A.; et al. Genome-wide association study identifies common variants associated with circulating vitamin E levels. Hum. Mol. Genet. 2011, 20, 3876–3883. [CrossRef] [PubMed]
24. Borel, P.; Preveraud, D.; Desmarchelier, C. Bioavailability of vitamin E in humans: An update. Nutr. Rev. 2013, 71, 319–331. [CrossRef]
25. Borel, P.; Desmarchelier, C. Genetic Variations Involved in Vitamin E Status. Int. J. Mol. Sci. 2016, 17, 2094. [CrossRef] [PubMed]
26. Borel, P.; Desmarchelier, C.; Nowicki, M.; Bott, R.; Tourniaire, F. Can Genetic Variability in α-Tocopherol Bioavailability Explain the Heterogeneous Response to α-Tocopherol Supplements? Antioxid. Redox Signal. 2015, 22, 669–678. [CrossRef] [PubMed]
27. Borel, P.; Desmarchelier, C. Bioavailability of Fat-Soluble Vitamins and Phytochemicals in Humans: Effects of Genetic Variation. Annu. Rev. Nutr. 2018, 38, 69–96. [CrossRef] [PubMed]
28. De Roos, B.; Brennan, L. Personalised Interventions—A Precision Approach for the Next Generation of Dietary Intervention Studies. Nutrients 2017, 9, 847. [CrossRef]
29. Anwar, K.; Iqbal, J.; Hussain, M.M. Mechanisms involved in vitamin E transport by primary enterocytes and in vivo absorption. J. Lipid Res. 2007, 48, 2028–2038. [CrossRef]
30. Yamanashi, Y.; Takada, T.; Kurauchi, R.; Tanaka, Y.; Komine, T.; Suzuki, H. Transporters for the Intestinal Absorption of Cholesterol, Vitamin E, and Vitamin K. J. Atheroscler. Thromb. 2017, 24, 347–359. [CrossRef]
31. Reboul, E.; Soayfane, Z.; Goncalves, A.; Cantiello, M.; Bott, R.; Nauze, M.; Tercé, F.; Collet, X.; Coméra, C. Respective contributions of intestinal Niemann-Pick C1-like 1 and scavenger receptor class B type I to cholesterol and tocopherol uptake: In vivo v. in vitro studies. Br. J. Nutr. 2017, 107, 1296–1304. [CrossRef]
32. Reboul, E.; Klein, A.; Bietrix, F.; Gleize, B.; Malezet-Desmoulins, C.; Schneider, M.; Margotat, A.; Lagrost, L.; Collet, X.; Borel, P. Scavenger Receptor Class B Type I (SR-BI) Is Involved in Vitamin E Transport across the Enterocyte. J. Biol. Chem. 2006, 281, 4739–4745. [CrossRef]
33. Shen, W.-J.; Azhar, S.; Kraemer, F.B. SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux. Annu. Rev. Physiol. 2018, 80, 95–116. [CrossRef] [PubMed]
34. Goncalves, A.; Roi, S.; Nowicki, M.; Niot, I.; Reboul, E. Cluster-determinant 36 (CD36) impacts on vitamin E postprandial response. Mol. Nutr. Food Res. 2014, 58, 2297–2306. [CrossRef] [PubMed]
35. Ulatowski, L.; Parker, R.; Davidson, C.; Yanjanin, N.; Kelley, T.J.; Corey, D.; Atkinson, J.; Porter, F.; Arai, H.; Walkley, S.U.; et al. Altered vitamin E status in Niemann-Pick type C disease. J. Lipid Res. 2011, 52, 1400–1410. [CrossRef] [PubMed]
36. Takada, T.; Suzuki, H. Molecular mechanisms of membrane transport of vitamin E. Mol. Nutr. Food Res. 2010, 54, 616–622. [CrossRef] [PubMed]
37. Oram, J.F.; Vaughan, A.M.; Stocker, R. ATP-binding cassette transporter A1 mediates cellular secretion of alpha-tocopherol. J. Biol. Chem. 2001, 276, 39898–39902. [CrossRef] [PubMed]
38. Traber, M.G. Mechanisms for the prevention of vitamin E excess. J. Lipid Res. 2013, 54, 2295–2306. [CrossRef]
39. Reboul, E.; Borel, P. Proteins involved in uptake, intracellular transport and basolateral secretion of fat-soluble vitamins and carotenoids by mammalian enterocytes. Prog. Lipid Res. 2011, 50, 388–402. [CrossRef]
40. Bowry, V.W.; Stanley, K.K.; Stocker, R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Natl. Acad. Sci. USA 1992, 89, 10316–10320. [CrossRef]
41. Romanchik, J.E.; Morel, D.W.; Harrison, E.H. Distributions of carotenoids and alpha-tocopherol among lipoproteins do not change when human plasma is incubated in vitro. J. Nutr. 1995, 125, 2610–2617. [PubMed]
42. Parker, R.S.; Sontag, T.J.; Swanson, J.E. Cytochrome P4503A-Dependent Metabolism of Tocopherols and Inhibition by Sesamin. Biochem. Biophys. Res. Commun. 2000, 277, 531–534. [CrossRef] [PubMed]
43. Hosomi, A.; Arita, M.; Sato, Y.; Kiyose, C.; Ueda, T.; Igarashi, O.; Arai, H.; Inoue, K. Affinity for α-tocopherol transfer protein as a determinant of the biological activities of vitamin E analogs. FEBS Lett. 1997, 409, 105–108. [CrossRef]
44. Kaempf-Rotzoll, D.E.; Traber, M.G.; Arai, H. Vitamin E and transfer proteins. Curr. Opin. Lipidol. 2003, 14, 249–254. [CrossRef] [PubMed]
45. Brigelius-Flohe, R.; Traber, M.G. Vitamin E: Function and metabolism. FASEB J. 1999, 13, 1145–1155. [CrossRef] [PubMed]
46. Pepino, M.Y.; Kuda, O.; Samovski, D.; Abumrad, N.A. Structure-Function of CD36 and Importance of Fatty Acid Signal Transduction in Fat Metabolism. Annu. Rev. Nutr. 2014, 34, 281–303. [CrossRef] [PubMed]
47. Holloway, G.P.; Bezaire, V.; Heigenhauser, G.J.F.; Tandon, N.N.; Glatz, J.F.C.; Luiken, J.J.F.P.; Bonen, A.; Spriet, L.L. Mitochondrial long chain fatty acid oxidation, fatty acid translocase/CD36 content and carnitine palmitoyltransferase I activity in human skeletal muscle during aerobic exercise. J. Physiol. 2006, 571, 201–210. [CrossRef]
48. Drover, V.A.; Nguyen, D.V.; Bastie, C.C.; Darlington, Y.F.; Abumrad, N.A.; Pessin, J.E.; London, E.; Sahoo, D.; Phillips, M.C. CD36 Mediates Both Cellular Uptake of Very Long Chain Fatty Acids and Their Intestinal Absorption in Mice. J. Biol. Chem. 2008, 283, 13108–13115. [CrossRef]
49. Nassir, F.; Wilson, B.; Han, X.; Gross, R.W.; Abumrad, N.A. CD36 is important for fatty acid and cholesterol uptake by the proximal but not distal intestine. J. Biol. Chem. 2007, 282, 19493–19501. [CrossRef]
50. Borel, P.; Lietz, G.; De Edelenyi, F.S.; Lecompte, S.; Curtis, P.; Goumidi, L.; Caslake, M.J.; Miles, E.A.; Packard, C.; Calder, P.C.; Mathers, J.C.; et al. CD36 and SR-BI Are Involved in Cellular Uptake of Provitamin A Carotenoids by Caco-2 and HEK Cells, and Some of Their Genetic Variants Are Associated with Plasma Concentrations of These Micronutrients in Humans. J. Nutr. 2013, 143, 448–456. [CrossRef]
51. Borel, P. Factors affecting intestinal absorption of highly lipophilic food microconstituents (fat-soluble vitamins, carotenoids and phytosterols). Clin. Chem. Lab. Med. 2003, 41, 979–994. [CrossRef] [PubMed]
52. Park, Y.M. CD36, a scavenger receptor implicated in atherosclerosis. Exp. Mol. Med. 2014, 46, e99. [CrossRef] [PubMed]
53. Jay, A.G.; Hamilton, J.A. The enigmatic membrane fatty acid transporter CD36: New insights into fatty acid binding and their effects on uptake of oxidized LDL. Prostagland. Leuk. Essent. Fat. Acids 2016. [CrossRef]
54. Zingg, J.-M.; Libinaki, R.; Lai, C.-Q.; Meydani, M.; Gianello, R.; Ogru, E.; Azzi, A. Modulation of gene expression by α-tocopherol and α-tocopheryl phosphate in THP-1 monocytes. Free Radic. Biol. Med. 2010, 49, 1989–2000. [CrossRef] [PubMed]
55. Laugerette, F.; Passilly-Degrace, P.; Patris, B.; Niot, I.; Febbraio, M.; Montmayeur, J.-P.; Besnard, P. CD36 involvement in orosensory detection of dietary lipids, spontaneous fat preference, and digestive secretions. J. Clin. Invest. 2005, 115, 3177–3184. [CrossRef] [PubMed]
56. Running, C.A.; Mattes, R.D.; Tucker, R.M. Fat taste in humans: Sources of within-and between-subject variability. Prog. Lipid Res. 2013, 52, 438–445. [CrossRef]
57. Ricciarelli, R.; Zingg, J.M.; Azzi, A. Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. Circulation 2000, 102, 82–87. [CrossRef]
58. Özer, N.K.; Negis, Y.; Aytan, N.; Villacorta, L.; Ricciarelli, R.; Zingg, J.-M.; Azzi, A. Vitamin E inhibits CD36 scavenger receptor expression in hypercholesterolemic rabbits. Atherosclerosis 2006, 184, 15–20. [CrossRef] [PubMed]
59. Devaraj, S.; Hugou, I.; Jialal, I. Alpha-tocopherol decreases CD36 expression in human monocyte-derived macrophages. J. Lipid Res. 2001, 42, 521–527.
60. Lecompte, S.; De Edelenyi, F.S.; Goumidi, L.; Maiani, G.; Moschonis, G.; Widhalm, K.; Kafatos, A.; Spinneker, A.; Breidenassel, C.; Dallongeville, J.; et al. Polymorphisms in the CD36/FAT gene are associated with plasma vitamin E concentrations in humans. Am. J. Clin. Nutr. 2011, 93, 644–651. [CrossRef]
61. Love-Gregory, L.; Sherva, R.; Schappe, T.; Qi, J.S.; Mccrea, J.; Klein, S.; Connelly, M.A.; Abumrad, N.A. Common CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profile. Hum. Mol. Genet. 2011, 20, 193–201. [CrossRef] [PubMed]
62. Love-Gregory, L.; Abumrad, N.A. CD36 genetics and the metabolic complications of obesity. Curr. Opin. Clin. Nutr. Metab. Care 2011, 14, 527–534. [CrossRef] [PubMed]
63. Varban, M.L. Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. Proc. Natl. Acad. Sci. USA 1998, 95, 4619–4624. [CrossRef] [PubMed]
64. West, M.; Greason, E.; Kolmakova, A.; Jahangiri, A.; Asztalos, B.; Pollin, T.I.; Rodriguez, A. Scavenger receptor class B type I protein as an independent predictor of high-density lipoprotein cholesterol levels in subjects with hyperalphalipoproteinemia. J. Clin. Endocrinol. Metab. 2009, 94, 1451–1457. [CrossRef] [PubMed]
65. Rigotti, A.; Trigatti, B.L.; Penman, M.; Rayburn, H.; Herz, J.; Krieger, M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc. Natl. Acad. Sci. USA 1997, 94, 12610–12615. [CrossRef] [PubMed]
66. Sattler, W.; Levak-Frank, S.; Radner, H.; Kostner, G.M.; Zechner, R. Muscle-specific overexpression of lipoprotein lipase in transgenic mice results in increased alpha-tocopherol levels in skeletal muscle. Biochem. J. 1996, 318, 15–19. [CrossRef] [PubMed]
67. Roberts, C.G.P.; Shen, H.; Mitchell, B.D.; Damcott, C.M.; Shuldiner, A.R.; Rodriguez, A. Variants in Scavenger Receptor Class B Type I Gene Are Associated with HDL Cholesterol Levels in Younger Women. Hum. Hered. 2007, 64, 107–113. [CrossRef] [PubMed]
68. Borel, P.; Moussa, M.; Reboul, E.; Lyan, B.; Defoort, C.; Vincent-Baudry, S.; Maillot, M.; Gastaldi, M.; Darmon, M.; Portugal, H.; et al. Human Plasma Levels of Vitamin E and Carotenoids Are Associated with Genetic Polymorphisms in Genes Involved in Lipid Metabolism. J. Nutr. 2007, 137, 2653–2659. [CrossRef] [PubMed]
69. Osgood, D.; Corella, D.; Demissie, S.; Cupples, L.A.; Wilson, P.W.F.; Meigs, J.B.; Schaefer, E.J.; Coltell, O.; Ordovas, J.M. Genetic Variation at the Scavenger Receptor Class B Type I Gene Locus Determines Plasma Lipoprotein Concentrations and Particle Size and Interacts with Type 2 Diabetes: The Framingham Study. J. Clin. Endocrinol. Metab. 2003, 88, 2869–2879. [CrossRef] [PubMed]
70. Manichaikul, A.; Wang, X.-Q.; Musani, S.K.; Herrington, D.M.; Post, W.S.; Wilson, J.G.; Rich, S.S.; Rodriguez, A. Association of the Lipoprotein Receptor SCARB1 Common Missense Variant rs4238001 with Incident Coronary Heart Disease. PLoS ONE 2015, 10, e0125497. [CrossRef]
71. Morabia, A.; Ross, B.M.; Costanza, M.C.; Cayanis, E.; Flaherty, M.S.; Alvin, G.B.; Das, K.; James, R.; Yang, A.-S.; Evagrafov, O.; et al. Population-based study of SR-BI genetic variation and lipid profile. Atherosclerosis 2004, 175, 159–168. [CrossRef] [PubMed]
72. Ma, R.; Zhu, X.; Yan, B. SCARB1 rs5888 gene polymorphisms in coronary heart disease: A systematic review and a meta-analysis. Gene 2018. [CrossRef] [PubMed]
73. Smalinskiene, A.; Petkeviciene, J.; Luksiene, D.; Jureniene, K.; Klumbiene, J.; Lesauskaite, V. Association between APOE, SCARB1, PPARα polymorphisms and serum lipids in a population of Lithuanian adults. Lipids Health Dis. 2013, 12, 120. [CrossRef] [PubMed]
74. Zerbib, J.; Seddon, J.M.; Richard, F.; Reynolds, R.; Leveziel, N.; Benlian, P.; Borel, P.; Feingold, J.; Munnich, A.; Soubrane, G.; et al. rs5888 variant of SCARB1 gene is a possible susceptibility factor for age-related macular degeneration. PLoS ONE 2009, 4, 1–6. [CrossRef] [PubMed]
75. Kamishikiryo, J.; Haraguchi, M.; Nakashima, S.; Tasaka, Y.; Narahara, H.; Sugihara, N.; Nakamura, T.; Morita, T. N-terminal domain of the cholesterol transporter Niemann–Pick C1-like 1 (NPC1L1) is essential for α-tocopherol transport. Biochem. Biophys. Res. Commun. 2017, 486, 476–480. [CrossRef] [PubMed]
76. Torres, S.; Balboa, E.; Zanlungo, S.; Enrich, C.; Garcia-Ruiz, C.; Fernandez-Checa, J.C. Lysosomal and Mitochondrial Liaisons in Niemann-Pick Disease. Front. Physiol. 2017, 8, 982. [CrossRef] [PubMed]
77. Meyre, D.; Delplanque, J.; Chèvre, J.-C.; Lecoeur, C.; Lobbens, S.; Gallina, S.; Durand, E.; Vatin, V.; Degraeve, F.; Proença, C.; et al. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat. Genet. 2009, 41, 157–159. [CrossRef] [PubMed]
78. Mielgo-ayuso, J.; Aparicio-ugarriza, R.; Castillo, A.; Ruiz, E. Physical Activity Patterns of the Spanish Population Are Mostly Determined by Sex and Age: Findings in the ANIBES Study. PLoS ONE 2016, 1–22. [CrossRef]
79. Schweitzer, M.; Makhoul, S.; Paliouras, M.; Beitel, L.K.; Gottlieb, B.; Trifiro, M.; Chowdhury, S.F.; Zaman, N.M.; Wang, E.; Davis, H.; et al. Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe. Atherosclerosis 2016, 246, 78–86. [CrossRef]
80. Narushima, K.; Takada, T.; Yamanashi, Y.; Suzuki, H. Niemann-pick C1-like 1 mediates alpha-tocopherol transport. Mol. Pharmacol. 2008, 74, 42–49. [CrossRef]
81. Yamanashi, Y.; Takada, T.; Suzuki, H. In-vitro characterization of the six clustered variants of Npc1l1 observed in cholesterol low absorbers. Pharmacogenet. Genom. 2009, 19, 884–892. [CrossRef] [PubMed]
82. Neufeld, E.B.; Remaley, A.T.; Demosky, S.J.; Stonik, J.A.; Cooney, A.M.; Comly, M.; Dwyer, N.K.; Zhang, M.; Blanchette-Mackie, J.; Santamarina-Fojo, S.; et al. Cellular Localization and Trafficking of the Human ABCA1 Transporter. J. Biol. Chem. 2001, 276, 27584–27590. [CrossRef] [PubMed]
83. Rosenson, R.S.; Brewer, H.B.; Davidson, W.S.; Fayad, Z.A.; Fuster, V.; Goldstein, J.; Hellerstein, M.; Jiang, X.-C.; Phillips, M.C.; Rader, D.J.; et al. Cholesterol Efflux and Atheroprotection. Circulation 2012, 125, 1905–1919. [CrossRef] [PubMed]
84. Brooks-Wilson, A.; Marcil, M.; Clee, S.M.; Zhang, L.H.; Roomp, K.; Van Dam, M.; Yu, L.; Brewer, C.; Collins, J.A.; Molhuizen, H.O.F.; et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 1999, 22, 336–345. [CrossRef] [PubMed]
85. Rust, S.; Rosier, M.; Funke, H.; Real, J.; Amoura, Z.; Piette, J.-C.; Deleuze, J.-F.; Brewer, H.B.; Duverger, N.; Denèfle, P.; Assmann, G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 1999, 22, 352–355. [CrossRef] [PubMed]
86. Orsó, E.; Broccardo, C.; Kaminski, W.E.; Böttcher, A.; Liebisch, G.; Drobnik, W.; Götz, A.; Chambenoit, O.; Diederich, W.; Langmann, T.; et al. Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and Abc1-deficient mice. Nat. Genet. 2000, 24, 192–196. [CrossRef]
87. Olivier, M.; Bott, R.; Frisdal, E.; Nowicki, M.; Plengpanich, W.; Desmarchelier, C.; Roi, S.; Quinn, C.M.; Gelissen, I.; Jessup, W.; et al. ABCG1 is involved in vitamin e efflux. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2014, 1841, 1741–1751. [CrossRef]
88. Kathiresan, S.; Willer, C.; Peloso, G.; Demissie, S. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 2008, 41, 56–65. [CrossRef]
89. Waterworth, D.M.; Ricketts, S.L.; Song, K.; Chen, L.; Zhao, J.H.; Ripatti, S.; Aulchenko, Y.S.; Zhang, W.; Yuan, X.; Lim, N.; et al. Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 2264–2276. [CrossRef]
90. Teslovich, T.M.; Musunuru, K.; Smith, A.V.; Edmondson, A.C.; Stylianou, I.M.; Koseki, M.; Pirruccello, J.P.; Ripatti, S.; Chasman, D.I.; Willer, C.J.; et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466, 707–713. [CrossRef]
91. Kathiresan, S.; Melander, O.; Guiducci, C.; Surti, A.; Burtt, N.P.; Rieder, M.J.; Cooper, G.M.; Roos, C.; Voight, B.F.; Havulinna, A.S.; et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 2008, 40, 189–197. [CrossRef] [PubMed]
92. Dumitrescu, L.; Goodloe, R.; Brown-Gentry, K.; Mayo, P.; Allen, M.; Jin, H.; Gillani, N.B.; Schnetz-Boutaud, N.; Dilks, H.H.; Crawford, D.C. Serum vitamins A and e as modifiers of lipid trait genetics in the National Health and Nutrition Examination Surveys as part of the Population Architecture using Genomics and Epidemiology (PAGE) study. Hum. Genet. 2012, 131, 1699–1708. [CrossRef] [PubMed]
93. Herrera, E.; Barbas, C. Vitamin E: Action, metabolism and perspectives. J. Physiol. Biochem. 2001, 57, 43–56. [CrossRef] [PubMed]
94. Drevon, C.A. Absorption, transport and metabolism of vitamin E. Free Radic. Res. Commun. 1991, 14, 229–246. [CrossRef] [PubMed]
95. West, K.P.; Cole, R.N.; Shrestha, S.; Schulze, K.J.; Lee, S.E.; Betz, J.; Nonyane, B.A.; Wu, L.S.-F.; Yager, J.D.; Groopman, J.D.; et al. A Plasma α-Tocopherome Can Be Identified from Proteins Associated with Vitamin E Status in School-Aged Children of Nepal. J. Nutr. 2015, 145, 2646–2656. [CrossRef] [PubMed]
96. Olivier, M.; Wang, X.; Cole, R.; Gau, B.; Kim, J.; Rubin, E.M.; Pennacchio, L.A. Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics 2004, 83, 912–923. [CrossRef] [PubMed]
97. Rousset, X.; Shamburek, R.; Vaisman, B.; Amar, M.; Remaley, A.T. Lecithin Cholesterol Acyltransferase: An Anti-or Pro-atherogenic Factor? Curr. Atheroscler. Rep. 2011, 13, 249–256. [CrossRef] [PubMed]
98. Holleboom, A.G.; Jakulj, L.; Franssen, R.; Decaris, J.; Vergeer, M.; Koetsveld, J.; Luchoomun, J.; Glass, A.; Hellerstein, M.K.; Kastelein, J.J.P.; et al. In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1. J. Lipid Res. 2013, 54, 1964–1971. [CrossRef] [PubMed]
99. Swanson, C.R.; Berlyand, Y.; Xie, S.X.; Alcalay, R.N.; Chahine, L.M.; Chen-Plotkin, A.S. Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson’s disease patients. Mov. Disord. 2015, 30, 1648–1656. [CrossRef] [PubMed]
100. De Luis, D.A.; Izaola, O.; Primo, D.; Aller, R. Implication of the rs670 variant of APOA1 gene with lipid profile, serum adipokine levels and components of metabolic syndrome in adult obese subjects. Clin. Nutr. 2017. [CrossRef] [PubMed]
101. Brien, P.J.O.; Alborn, W.E.; Sloan, J.H.; Ulmer, M.; Boodhoo, A.; Knierman, M.D.; Schultze, A.E.; Konrad, R.J. The Novel Apolipoprotein A5 Is Present in Human Serum, Is Associated with VLDL, HDL, and Chylomicrons, and Circulates at Very Low Concentrations Compared with Other Apolipoproteins. Clin. Chem. 2005, 51, 351–359. [CrossRef] [PubMed]
102. Hegele, R.A. Plasma lipoproteins: Genetic influences and clinical implications. Nat. Rev. Genet. 2009, 10, 109–121. [CrossRef] [PubMed]
103. Zhao, S.P.; Hu, S.; Li, J.; Hu, M.; Liu, Q.; Wu, L.J.; Zhang, T. Association of human serum apolipoprotein A5 with lipid profiles affected by gender. Clin. Chim. Acta 2007, 376, 68–71. [CrossRef] [PubMed]
104. Huang, X.S.; Zhao, S.P.; Hu, M.; Bai, L.; Zhang, Q.; Zhao, W. Decreased apolipoprotein A5 is implicated in insulin resistance-related hypertriglyceridemia in obesity. Atherosclerosis 2010, 210, 563–568. [CrossRef] [PubMed]
105. Guardiola, M.; Ribalta, J. Update on APOA5 Genetics: Toward a Better Understanding of Its Physiological Impact. Curr. Atheroscler. Rep. 2017, 19. [CrossRef]
106. Su, X.; Kong, Y.; Peng, D.Q. New insights into apolipoprotein A5 in controlling lipoprotein metabolism in obesity and the metabolic syndrome patients. Lipids Health Dis. 2018, 17, 1–10. [CrossRef]
107. Girona, J.; Guardiola, M.; Cabre, A.; Manzanares, J.M.; Heras, M. The apolipoprotein A5 gene–1131 T™ C polymorphism affects vitamin E plasma concentrations in type 2 diabetic patients. Clin. Chem. Lab. Med. 2008, 46, 453–457. [CrossRef]
108. Guardiola, M.; Ribalta, J.; Gómez-Coronado, D.; Lasunción, M.A.; de Oya, M.; Garcés, C. The apolipoprotein A5 (APOA5) gene predisposes Caucasian children to elevated triglycerides and vitamin E (Four Provinces Study). Atherosclerosis 2010, 212, 543–547. [CrossRef]
109. Dallongeville, J.; Cottel, D.; Wagner, A.; Ducimetière, P.; Ruidavets, J.-B.; Arveiler, D.; Bingham, A.; Ferrières, J.; Amouyel, P.; Meirhaeghe, A. The APOA5 Trp19 allele is associated with metabolic syndrome via its association with plasma triglycerides. BMC Med. Genet. 2008, 9, 84. [CrossRef]
110. ′ -monooxygenase 1 gene affects circulating levels of carotenoids: A genome-wide association study. Am. J. Hum. Genet. 2008, 84, 123–133. [CrossRef]
111. Wazen, R.M.; Kuroda, S.; Nishio, C.; Sellin, K.; Brunski, J.B.; Nanci, A. Gene expression profiling and histomorphometric analyses of the early bone healing response around nanotextured implants. Nanomedicine 2013, 8, 1385–1395. [CrossRef] [PubMed]
112. Pussinen, P.J.; Jauhiainen, M.; Metso, J.; Pyle, L.E.; Marcel, Y.L.; Fidge, N.H.; Ehnholm, C. Binding of phospholipid transfer protein (PLTP) to apolipoproteins A-I and A-II: Location of a PLTP binding domain in the amino terminal region of apoA-I. J. Lipid Res. 1998, 39, 152–161. [PubMed]
113. Massey, J.B. Kinetics of transfer of α-tocopherol between model and native plasma lipoproteins. Biochim. Biophys. Acta (BBA) Lipids Lipid Metab. 1984, 793, 387–392. [CrossRef]
114. Xiao, J.; Zhang, F.; Wiltshire, S.; Hung, J.; Jennens, M.; Beilby, J.P.; Thompson, P.L.; McQuillan, B.M.; McCaskie, P.A.; Carter, K.W.; et al. The apolipoprotein AII rs5082 variant is associated with reduced risk of coronary artery disease in an Australian male population. Atherosclerosis 2008, 199, 333–339. [CrossRef]
115. Millar, J.S.; Lichtenstein, A.H.; Ordovas, J.M.; Dolnikowski, G.G.; Schaefer, E.J. Human triglyceride-rich lipoprotein apo E kinetics and its relationship to LDL apo B-100 metabolism. Atherosclerosis 2001, 155, 477–485. [CrossRef]
116. Farrer, L.A.; Cupples, L.A.; Haines, J.L.; Hyman, B.; Kukull, W.A.; Mayeux, R.; Myers, R.H.; Pericak-Vance, M.A.; Risch, N.; van Duijn, C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278, 1349–1356. [CrossRef]
117. Liehn, E.A.; Ponomariov, V.; Diaconu, R.; Streata, I.; Ioana, M.; Crespo-Avilan, G.E.; Hernández-Reséndiz, S.; Cabrera-Fuentes, H.A. Apolipoprotein E in Cardiovascular Diseases: Novel Aspects of an Old-fashioned Enigma. Arch. Med. Res. 2018. [CrossRef]
118. Schächter, F.; Faure-Delanef, L.; Guénot, F.; Rouger, H.; Froguel, P.; Lesueur-Ginot, L.; Cohen, D. Genetic associations with human longevity at the APOE and ACE loci. Nat. Genet. 1994, 6, 29–32. [CrossRef]
119. Song, Y.; Stampfer, M.J.; Liu, S. Meta-analysis: Apolipoprotein E genotypes and risk for coronary heart disease. Ann. Intern. Med. 2004, 141, 137–147. [CrossRef]
120. Tall, A.R. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J. Clin. Invest. 1990, 86, 379–384. [CrossRef]
121. Huebbe, P.; Lodge, J.K.; Rimbach, G. Implications of apolipoprotein E genotype on inflammation and vitamin E status. Mol. Nutr. Food Res. 2010, 54, 623–630. [CrossRef] [PubMed]
122. Dose, J.; Huebbe, P.; Nebel, A.; Rimbach, G. APOE genotype and stress response—A mini review. Lipids Health Dis. 2016, 15, 121. [CrossRef] [PubMed]
123. Artiga, M.J.; Bullido, M.J.; Sastre, I.; Recuero, M.; García, M.A.; Aldudo, J.; Vázquez, J.; Valdivieso, F. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett. 1998, 421, 105–108. [CrossRef]
124. Bullido, M.J.; Artiga, M.J.; Recuero, M.; Sastre, I.; García, M.A.; Aldudo, J.; Lendon, C.; Han, S.W.; Morris, J.C.; Frank, A.; et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer’s dementia. Nat. Genet. 1998, 18, 69–71. [CrossRef] [PubMed]
125. Aulchenko, Y.S.; Ripatti, S.; Lindqvist, I.; Boomsma, D.; Heid, I.M.; Pramstaller, P.P.; Penninx, B.W.J.H.; Janssens, A.C.J.W.; Wilson, J.F.; Spector, T.; et al. ENGAGE Consortium Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat. Genet. 2009, 41, 47–55. [CrossRef] [PubMed]
126. Sabatti, C.; Service, S.K.; Hartikainen, A.-L.; Pouta, A.; Ripatti, S.; Brodsky, J.; Jones, C.G.; Zaitlen, N.A.; Varilo, T.; Kaakinen, M.; et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat. Genet. 2009, 41, 35–46. [CrossRef] [PubMed]
127. Huggins, G.S.; Papandonatos, G.D.; Erar, B.; Belalcazar, L.M.; Brautbar, A.; Ballantyne, C.; Kitabchi, A.E.; Wagenknecht, L.E.; Knowler, W.C.; Pownall, H.J.; et al. Do Genetic Modifiers of High-Density Lipoprotein Cholesterol and Triglyceride Levels Also Modify Their Response to a Lifestyle Intervention in the Setting of Obesity and Type-2 Diabetes Mellitus? Circ. Cardiovasc. Genet. 2013, 6, 391–399. [CrossRef] [PubMed]
128. Yamada, Y.; Matsuo, H.; Warita, S.; Watanabe, S.; Kato, K.; Oguri, M.; Yokoi, K.; Metoki, N.; Yoshida, H.; Satoh, K.; et al. Prediction of genetic risk for dyslipidemia. Genomics 2007, 90, 551–558. [CrossRef] [PubMed]
129. Goncalves, A.; Amiot, M.-J. Fat-soluble micronutrients and metabolic syndrome. Curr. Opin. Clin. Nutr. Metab. Care 2017, 20, 1. [CrossRef] [PubMed]
130. Ulatowski, L.; Dreussi, C.; Noy, N.; Barnholtz-Sloan, J.; Klein, E.; Manor, D. Expression of the a-tocopherol transfer protein gene is regulated by oxidative stress and common single-nucleotide polymorphisms. Free Radic. Biol. Med. 2012, 53, 2318–2326. [CrossRef] [PubMed]
131. Galli, F.; Stabile, A.M.; Betti, M.; Conte, C.; Pistilli, A.; Rende, M.; Floridi, A.; Azzi, A. The effect of α-And γ-tocopherol and their carboxyethyl hydroxychroman metabolites on prostate cancer cell proliferation. Arch. Biochem. Biophys. 2004, 423, 97–102. [CrossRef] [PubMed]
132. Uto-Kondo, H.; Kiyose, C.; Ohmori, R.; Saito, H.; Taguchi, C.; Kishimoto, Y.; Machida, N.; Hasegawa, M.; Yoshioka, E.; Saita, E.; et al. The coantioxidative effects of carboxyethyl-6-hydroxychromans and alpha-tocopherol. J. Nutr. Sci. Vitaminol. (Tokyo) 2007, 53, 301–305. [CrossRef]
133. Grammas, P.; Hamdheydari, L.; Benaksas, E.J.; Mou, S.; Pye, Q.N.; Wechter, W.J.; Floyd, R.A.; Stewart, C.; Hensley, K. Anti-inflammatory effects of tocopherol metabolites. Biochem. Biophys. Res. Commun. 2004, 319, 1047–1052. [CrossRef] [PubMed]
134. ′ -carboxyethyl)-6-hydroxychroman (alpha-CEHC), a vitamin E metabolite. Free Radic. Res. 2002, 36, 915–921. [CrossRef] [PubMed]
135. Wallert, M.; Schmölz, L.; Galli, F.; Birringer, M.; Lorkowski, S. Regulatory metabolites of vitamin E and their putative relevance for atherogenesis. Redox Boil. 2014, 2, 495–503. [CrossRef]
136. Schubert, M.; Kluge, S.; Schmölz, L.; Wallert, M.; Galli, F.; Birringer, M.; Lorkowski, S. Long-Chain Metabolites of Vitamin E: Metabolic Activation as a General Concept for Lipid-Soluble Vitamins? Antioxidants 2018, 7, 10. [CrossRef] [PubMed]
137. Arita, M.; Sato, Y.; Miyata, A.; Tanabe, T.; Takahashi, E.; Kayden, H.J.; Arai, H.; Inoue, K. Human alpha-tocopherol transfer protein: CDNA cloning, expression and chromosomal localization. Biochem. J. 1995, 306, 437–443. [CrossRef] [PubMed]
138. Shaw, H.-M.; Huang, C.-J. Liver α-Tocopherol Transfer Protein and Its mRNA Are Differentially Altered by Dietary Vitamin E Deficiency and Protein Insufficiency in Rats. J. Nutr. 1998, 128, 2348–2354. [CrossRef] [PubMed]
139. Trujillo-Martín, M.M.; Serrano-Aguilar, P.; Monton-Álvarez, F.; Carrillo-Fumero, R. Effectiveness and safety of treatments for degenerative ataxias: A systematic review. Mov. Disord. 2009, 24, 1111–1124. [CrossRef]
140. Wright, M.E.; Peters, U.; Gunter, M.J.; Moore, S.C.; Lawson, K.A.; Yeager, M.; Weinstein, S.J.; Snyder, K.; Virtamo, J.; Albanes, D. Association of Variants in Two Vitamin E Transport Genes with Circulating Vitamin E Concentrations and Prostate Cancer Risk. Cancer Res. 2009, 69, 1429–1438. [CrossRef]
141. Zimmer, S.; Stocker, A.; Sarbolouki, M.N.; Spycher, S.E.; Sassoon, J.; Azzi, A. A novel human tocopherol-associated protein: Cloning, in vitro expression, and characterization. J. Biol. Chem. 2000, 275, 25672–25680. [CrossRef] [PubMed]
142. Yamauchi, J.; Iwamoto, T.; Kida, S.; Masushige, S.; Yamada, K.; Esashi, T. Tocopherol-associated protein is a ligand-dependent transcriptional activator. Biochem. Biophys. Res. Commun. 2001, 285, 295–299. [CrossRef] [PubMed]
143. Lauridsen, C.; Jensen, S.K. α-Tocopherol incorporation in mitochondria and microsomes upon supranutritional vitamin E supplementation. Genes Nutr. 2012, 7, 475–482. [CrossRef] [PubMed]
144. Parker, R.S.; Sontag, T.J.; Swanson, J.E.; Mccormick, C.C. Discovery, Characterization, and Significance of the Cytochrome P450 ω-Hydroxylase Pathway of Vitamin E Catabolism. Ann. N. Y. Acad. Sci. 2004, 1031, 13–21. [CrossRef]
145. Sontag, T.J.; Parker, R.S. Cytochrome P450 ω-Hydroxylase Pathway of Tocopherol Catabolism. J. Biol. Chem. 2002, 277, 25290–25296. [CrossRef]
146. Birringer, M.; Drogan, D.; Brigelius-Flohe, R. Tocopherols are metabolized in HepG2 cells by side chain omega-oxidation and consecutive beta-oxidation. Free Radic. Biol. Med. 2001, 31, 226–232. [CrossRef]
147. Bardowell, S.A.; Duan, F.; Manor, D.; Swanson, J.E.; Parker, R.S. Disruption of Mouse Cytochrome P450 4f14 (Cyp4f14 Gene) Causes Severe Perturbations in Vitamin E Metabolism. J. Biol. Chem. 2012, 287, 26077–26086. [CrossRef] [PubMed]
148. Döring, F.; Rimbach, G.; Lodge, J.K. In silico search for single nucleotide polymorphisms in genes important in vitamin E homeostasis. IUBMB Life 2004, 56, 615–620. [CrossRef] [PubMed]
149. Stec, D.E.; Roman, R.J.; Flasch, A.; Rieder, M.J. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol. Genomics. 2007, 74–81. [CrossRef] [PubMed]
150. Bardowell, S.A.; Stec, D.E.; Parker, R.S. Common variants of cytochrome P450 4F2 exhibit altered vitamin E-{omega}-hydroxylase specific activity. J. Nutr. 2010, 140, 1901–1906. [CrossRef]
151. Athinarayanan, S.; Wei, R.; Zhang, M.; Bai, S.; Traber, M.G.; Yates, K.; Cummings, O.W.; Molleston, J.; Liu, W.; Chalasani, N. Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials. PLoS ONE 2014, 9. [CrossRef] [PubMed]
152. Bou Ghanem, E.N.; Lee, J.N.; Joma, B.H.; Meydani, S.N.; Leong, J.M.; Panda, A. The Alpha-Tocopherol Form of Vitamin E Boosts Elastase Activity of Human PMNs and Their Ability to Kill Streptococcus pneumoniae. Front. Cell. Infect. Microbiol. 2017, 7, 161. [CrossRef] [PubMed]
153. Meydani, S.N.; Barklund, M.P.; Liu, S.; Meydani, M.; Miller, R.A.; Cannon, J.G.; Morrow, F.D.; Rocklin, R.; Blumberg, J.B. Vitamin E supplementation enhances cell-mediated immunity in healthy elderly subjects. Am. J. Clin. Nutr. 1990, 52, 557–563. [CrossRef] [PubMed]
154. Meydani, S.N.; Meydani, M.; Blumberg, J.B.; Leka, L.S.; Siber, G.; Loszewski, R.; Thompson, C.; Pedrosa, M.C.; Diamond, R.D.; Stollar, B.D. Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. JAMA 1997, 277, 1380–1386. [CrossRef] [PubMed]
155. Wilson, A.G.; Symons, J.A.; McDowell, T.L.; McDevitt, H.O.; Duff, G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. USA 1997, 94, 3195–3199. [CrossRef] [PubMed]
156. Belisle, S.E.; Leka, L.S.; Delgado-Lista, J.; Jacques, P.F.; Ordovas, J.M.; Meydani, S.N. Polymorphisms at cytokine genes may determine the effect of vitamin E on cytokine production in the elderly. J. Nutr. 2009, 139, 1855–1860. [CrossRef] [PubMed]
157. England, A.; Valdes, A.M.; Slater-jefferies, J.L.; Gill, R.; Howell, W.M.; Calder, P.C.; Grimble, R.F. Variants in the genes encoding TNF-a, IL-10, and GSTP1 influence the effect of a-tocopherol on inflammatory cell responses in healthy men. Am. J. Clin. Nutr. 2012, 1461–1467. [CrossRef] [PubMed]
158. Seibold, P.; Hein, R.; Schmezer, P.; Hall, P.; Liu, J.; Dahmen, N.; Flesch-Janys, D.; Popanda, O.; Chang-Claude, J. Polymorphisms in oxidative stress-related genes and postmenopausal breast cancer risk. Int. J. Cancer 2011, 129, 1467–1476. [CrossRef] [PubMed]
159. Mansego, M.L.; De Marco, G.; Ivorra, C.; Lopez-Izquierdo, R.; Morcillo, S.; Rojo-Martínez, G.; González-Albert, V.; Martinez, F.; Soriguer, F.; Martín-Escudero, J.C.; et al. The nutrigenetic influence of the interaction between dietary vitamin E and TXN and COMT gene polymorphisms on waist circumference: A case control study. J. Transl. Med. 2015, 13, 286. [CrossRef]
160. Mellini, P.; Valente, S.; Mai, A. Sirtuin modulators: An updated patent review (2012 – 2014). Expert Opin. Ther. Pat. 2014, 25, 1–11. [CrossRef]
161. Zillikens, M.C.; Van Meurs, J.B.J.; Rivadeneira, F.; Hofman, A.; Oostra, B.A.; Sijbrands, E.J.G. Interactions between dietary vitamin E intake and SIRT1 genetic variation influence body mass index 1–3. Am. J. Clin. Nutr. 2010, 91, 1387–1393. [CrossRef] [PubMed]
162. Clark, S.J.; Falchi, M.; Olsson, B.; Jacobson, P.; Cauchi, S.; Balkau, B.; Marre, M.; Lantieri, O.; Andersson, J.C.; Jernås, M.; et al. Association of Sirtuin 1 (SIRT1) Gene SNPs and Transcript Expression Levels With Severe Obesity. Obesity 2012. [CrossRef] [PubMed]